IBRANCE® (palbociclib)| P-REALITY overview | PfizerPro Ireland

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

Clinical efficacy & safety

PALOMA-2

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

PALOMA-2 summary

PALOMA-3

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

Safety

Safety overview

Pooled laboratory abnormalities

PALOMA-2 AEs

PALOMA-3 AEs

Selected safety features

IBRANCE long-term safety

GI and liver toxicities

Effect of IBRANCE on QTc interval

Elderly patients

Visceral disease patients

Dose reduction effect on efficacy

RW evidence

Value of RWE

What is real-world evidence?

What is the value of RWE?

P-REALITY and P-REALITY X

P-REALITY Overview

P-REALITY OS and rwPFS

P-REALITY X Overview

P-REALITY X OS and rwPFS

IRIS

IRIS Overview

IRIS PFS and OS

POLARIS

POLARIS Overview

POLARIS Patient-Reported Outcomes

MADELINE

MADELINE Overview

MADELINE Patient Characteristics

MADELINE Patient-Reported Outcomes

PalomAGE

PalomAGE Overview

RWE in Older Patients with mBC

P-VERIFY

P-VERIFY Study

Patient-reported outcomes

PALOMA-2: FACT-B scores

PALOMA-3: EORTC QLQ-C30 scores

PALOMA-3: Time to deterioration in pain symptoms

Dosing

Recommended dosing schedule

Recommended dose modifications for AEs

Monitoring

One scheduled monitoring provision

Prescribing Information

Resources

Materials

P-REALITY overview

P-REALITY (Palbociclib REAL-world 1^st-line ComparaTive Effectiveness Study) was a comparison of the effectiveness of 1^st-line IBRANCE in combination with letrozole vs letrozole alone.¹

P-REALITY study design

A total of 1430 patients with ≥3 months of follow-up received IBRANCE in combination with letrozole or letrozole alone in the 1st-line setting¹

sIPTW was used to balance patient characteristics and minimize bias caused by lack of randomization^*1

The study included a heterogeneous US population of women in terms of age, race, time to metastatic diagnosis, performance status, bone and visceral involvement¹

Select baseline patient characteristics (after sIPTW adjustment)^*1

Adapted from DeMichele A, et al. 2021.¹

Real-world PFS was defined as the number of months from start of IBRANCE in combination with letrozole or letrozole alone to death or disease progression. Disease progression was determined by the record assessment of the treating clinician based on radiology, pathology, clinical assessment, or laboratory evidence. Patients who did not die or have disease progression were censored at the date of initiation of next line of therapy for those with 2 or more lines of therapy or their last visit during the study period (February 2015–May 2019) for patients with only one line of therapy.

Visceral disease was defined as metastatic disease in the lung and/or liver. Patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases.

Bone-only disease was defined as metastatic disease in the bone only.

de novo vs not de novo were used as categories for initial diagnosis to metastatic diagnosis.

ECOG performance status score was not documented for the remaining patients. The balance in important prognostic baseline characteristics was assessed using a standardized differences approach, with a standardized difference of ≥0.01 considered indicative of practical significance. The total patient population for different subgroups varied due to the application of sIPTW. Therefore, the total n number for each subgroup may not have always equalled the N number of the treatment arm (due to rounding error and categorization differences). Calculated percentages were based on the number of patients reported within each subgroup.

Explore More

P-REALITY OS and rwPFS

Explore more

P-REALITY X overview

Explore more

ECOG = Eastern Cooperative Oncology Group; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; LET = letrozole; mBC = metastatic breast cancer; N/n = number of patients; PFS = progression-free survival; OS = overall survival; sIPTW = stabilized inverse probability of treatment weighting.

References:

DeMichele A, et al. Breast Cancer Res. 2021;23:37.

P-REALITY and P-REALITY X

IBRANCE Summary of Product Characteristics

Product Characteristics

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0649. August 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0832. October 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0832. October 2024